|Company name||Esperion Therapeutics, Inc.|
|Class period||February 22, 2017 – May 2, 2018|
|Lead plaintiff deadline||July 6, 2018|
|Court||Eastern District of Michigan|
NEW YORK, May 8, 2018 – Bragar Eagel & Squire, P.C. announces to investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Michigan on behalf of all persons or entities who purchased or otherwise acquired Esperion Therapeutics, Inc. (NASDAQ: ESPR) securities securities between February 22, 2017 and May 2, 2018 (the “Class Period”). Investors have until July 6, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and (ii) as a result of the foregoing, Esperion’s public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Esperion securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.